Migraine Drugs Global Market Report 2025

Description

Migraine drugs are medications designed to address a neurological condition characterized by intense, throbbing headaches. These drugs operate by targeting various physiological mechanisms responsible for causing migraines.

The primary classes of migraine drugs include triptans, beta-blockers, angiotensin blockers, tricyclics, and anticonvulsants. Triptans, for example, work by altering blood circulation in the brain and modulating how the brain processes pain signals. These drugs can be administered through various routes, such as oral or injectable, and are utilized by diverse end-users, including hospitals and clinics, retail pharmacies, online pharmacies, and others.

The migraine drugs market research report is one of a series of new reports from The Business Research Company that provides migraine drugs market statistics, including migraine drugs industry global market size, regional shares, competitors with a migraine drugs market share, detailed migraine drugs market segments, market trends and opportunities, and any further data you may need to thrive in the migraine drugs industry. This migraine drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The migraine drugs market size has grown strongly in recent years. It will grow from $5.38 billion in 2024 to $5.77 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to advancements in drug formulations, increased awareness and diagnosis, stress and lifestyle factors, expansion of generic drugs, emergence of cgrp inhibitors.

The migraine drugs market size is expected to see strong growth in the next few years. It will grow to $7.22 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to personalized medicine approaches, telemedicine and remote consultations, healthcare policy and insurance coverage, increasing global migraine burden, combination therapies. Major trends in the forecast period include targeted therapies, telemedicine and remote consultations, patient-centric approaches, digital therapeutics, biosimilars in migraine treatment, clinical research and trials.

The anticipated growth of the migraine drugs market is expected to be propelled by the increasing female population. The female population, encompassing females across all age groups in each country or region during a specific period, plays a crucial role in driving the demand for migraine medications. The prevalence of migraines is notably higher in the female population compared to males, influenced by a combination of genetic, hormonal, and environmental factors. As of 2022, according to the World Population Prospects 2022 released by the United Nations, the global female population is estimated at 4.00 billion, constituting 49.75% of the world population. Projections suggest that females will outnumber males by the year 2049. Consequently, the expanding female population serves as a key driver behind the growth of the migraine drugs market.

The increase in the prevalence of migraines is expected to further contribute to the growth of the migraine drug market in the coming years. Migraine headaches, characterized by recurring episodes of pulsing and pounding pain on one side of the brain, have become more prevalent, leading to a rising demand for effective migraine medications. This surge in prevalence fuels innovation and sales growth as pharmaceutical companies develop and provide therapies to address the needs of an expanding patient population. For instance, as reported in March 2023 by the Migraine Australia 2022-23 Pre-Budget Submissions, a document released by the Australian Treasury, Australia has one of the highest migraine rates globally (28%), affecting one in every four people. This prevalence surpasses that of type 2 diabetes, epilepsy, and asthma combined. Therefore, the increasing prevalence of migraines stands as a significant driver for the growth of the migraine drug market.

Major companies operating in the migraine drugs market are concentrating on the development of innovative products to enhance patient care and gain a competitive advantage. One such example is Zavzpret, a nasal spray medication designed for the acute treatment of migraines with or without aura in adults. For example, in March 2023, Pfizer, a US-based pharmaceutical company, obtained approval from the Food and Drug Administration (FDA) for Zavzpret. It is the first and only approved zavegepant (CGRP receptor antagonist) nasal spray for the acute treatment of migraine. Targeting the calcitonin gene-related peptide (CGRP), Zavzpret offers a new treatment option, particularly for individuals experiencing migraines with nausea and vomiting, as well as for those unable to use triptans due to cardiovascular risks.

In May 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, acquired BioHaven Pharmaceutical Holding Company Ltd. for $11.6 billion. Through this acquisition, Pfizer aims to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraines. This strategic move underscores the pharmaceutical industry's commitment to advancing migraine drug development and addressing patient needs.

Major companies operating in the migraine drugs market report are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Merck & Co. Inc., AbbVie Inc., AbbVie Inc., Sanofi SA, Novartis AG, AstraZeneca, Abbott Laboratories, GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Dr Reddy's Laboratories Ltd., H. Lundbeck A/S, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Neurelis Inc., ALDER BIOPHARMACEUTICALS INC., eNeura Inc., Winston Pharmaceuticals Ltd.

North America was the largest region in the migraine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the migraine drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the migraine drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The migraine drugs market consists of sales of analgesics, ergotamines, sumatriptan, and rizatriptan. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Migraine Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on migraine drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for migraine drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The migraine drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Class: Triptans; Betablockers; Angiotensin Blockers; Tricyclics; Anticonvulsants
2) By Route of Administration: Oral; Injectable; Other Routes
3) By End-User: Hospitals And Clinics; Retail Pharmacy; Online Pharmacy; Other End Users
Subsegments:
1) By Triptans: Sumatriptan; Rizatriptan; Zolmitriptan; Eletriptan
2) By Beta Blockers: Propranolol; Metoprolol; Timolol
3) By Angiotensin Blockers: Candesartan; Losartan
4) By Tricyclics: Amitriptyline; Nortriptyline
5) By Anticonvulsants: Topiramate; Valproate
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Bayer AG; Merck & Co. Inc.; AbbVie Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r28524

1. Executive Summary

2. Migraine Drugs Market Characteristics

3. Migraine Drugs Market Trends And Strategies

4. Migraine Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Migraine Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Migraine Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Migraine Drugs Market Growth Rate Analysis
5.4. Global Migraine Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Migraine Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Migraine Drugs Total Addressable Market (TAM)

6. Migraine Drugs Market Segmentation

6.1. Global Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Triptans
Betablockers
Angiotensin Blockers
Tricyclics
Anticonvulsants
6.2. Global Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectable
Other Routes
6.3. Global Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals And Clinics
Retail Pharmacy
Online Pharmacy
Other End Users
6.4. Global Migraine Drugs Market, Sub-Segmentation Of Triptans, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Sumatriptan
Rizatriptan
Zolmitriptan
Eletriptan
6.5. Global Migraine Drugs Market, Sub-Segmentation Of Beta Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Propranolol
Metoprolol
Timolol
6.6. Global Migraine Drugs Market, Sub-Segmentation Of Angiotensin Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Candesartan
Losartan
6.7. Global Migraine Drugs Market, Sub-Segmentation Of Tricyclics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Amitriptyline
Nortriptyline
6.8. Global Migraine Drugs Market, Sub-Segmentation Of Anticonvulsants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Topiramate
Valproate

7. Migraine Drugs Market Regional And Country Analysis

7.1. Global Migraine Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Migraine Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Migraine Drugs Market

8.1. Asia-Pacific Migraine Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Migraine Drugs Market

9.1. China Migraine Drugs Market Overview
9.2. China Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Migraine Drugs Market

10.1. India Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Migraine Drugs Market

11.1. Japan Migraine Drugs Market Overview
11.2. Japan Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Migraine Drugs Market

12.1. Australia Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Migraine Drugs Market

13.1. Indonesia Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Migraine Drugs Market

14.1. South Korea Migraine Drugs Market Overview
14.2. South Korea Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Migraine Drugs Market

15.1. Western Europe Migraine Drugs Market Overview
15.2. Western Europe Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Migraine Drugs Market

16.1. UK Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Migraine Drugs Market

17.1. Germany Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Migraine Drugs Market

18.1. France Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Migraine Drugs Market

19.1. Italy Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Migraine Drugs Market

20.1. Spain Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Migraine Drugs Market

21.1. Eastern Europe Migraine Drugs Market Overview
21.2. Eastern Europe Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Migraine Drugs Market

22.1. Russia Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Migraine Drugs Market

23.1. North America Migraine Drugs Market Overview
23.2. North America Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Migraine Drugs Market

24.1. USA Migraine Drugs Market Overview
24.2. USA Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Migraine Drugs Market

25.1. Canada Migraine Drugs Market Overview
25.2. Canada Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Migraine Drugs Market

26.1. South America Migraine Drugs Market Overview
26.2. South America Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Migraine Drugs Market

27.1. Brazil Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Migraine Drugs Market

28.1. Middle East Migraine Drugs Market Overview
28.2. Middle East Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Migraine Drugs Market

29.1. Africa Migraine Drugs Market Overview
29.2. Africa Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Migraine Drugs Market Competitive Landscape And Company Profiles

30.1. Migraine Drugs Market Competitive Landscape
30.2. Migraine Drugs Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Migraine Drugs Market Other Major And Innovative Companies

31.1. AbbVie Inc.
31.2. Sanofi SA
31.3. Novartis AG
31.4. AstraZeneca
31.5. Abbott Laboratories
31.6. GlaxoSmithKline plc.
31.7. Eli Lilly and Company
31.8. Amgen Inc.
31.9. Otsuka Holdings Co. Ltd.
31.10. Teva Pharmaceutical Industries Ltd.
31.11. Bausch Health Companies Inc.
31.12. Eisai Co. Ltd.
31.13. Dr Reddys Laboratories Ltd.
31.14. H. Lundbeck A/S
31.15. Amneal Pharmaceuticals Inc.

32. Global Migraine Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Migraine Drugs Market

34. Recent Developments In The Migraine Drugs Market

35. Migraine Drugs Market High Potential Countries, Segments and Strategies

35.1 Migraine Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Migraine Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Migraine Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer